Buy Siberia Snus

Keeping Siberia Snus out of the conversation is impossible when discussing one of the strongest snus brands. Siberia has churned out high-quality nicotine and snussz since its creation. It's one of the reasons why this brand continues to dominate the snus scene worldwide.

Some Siberia products have nicotine levels exceeding 40 mg per gram. Most of their products are 5 times stronger than the other snussz products on the market. If you're a hardcore snus fan, you shouldn't miss out on this brand.


History of Siberia snus

Siberia is a subsidiary of GN Tobacco. GN is a major Swedish snus and tobacco manufacturer. It wouldn't be wrong to call them a monopoly in the tobacco product market. However, GN is not a dark monopolistic overlord who exploits the masses. GN Tobacco has always tried to create new, innovative products at affordable prices.

You can catch glimpses of GN's vision and goals in Siberia. With one of the world's best snus catalogues and iconic flavours, Siberia snus is perfect for experienced users of snussz.


Enticing Siberia flavours

You can try out any Siberian snus flavour for an extreme snus experience. However, here's a brief overview of what they offer. Like most snus producers, Siberia offers two iconic flavours. where would snussz even be without the taste of tobacco? With this thought in mind, this brand has created some fantastic snussz products. These products have a spicy taste reminiscent of tobacco. Some delectable products even have hints of bergamot and other enticing ingredients.

If you want to enjoy the legacy of Sweden and snussz, then you need to try out a product with this classic flavour. You should try out Siberia's Brown Portions and Black Portions to experience the magic of this flavour. If you would like to go a step further, then try chewing bags.


Mint, Spearmint, and Menthol

If you're a fan of powerful nicotine kicks, but don't like tobacco flavour, then don't worry. This brand offers mint-flavoured snus. You can experience these minty flavours with most of the White Dry portions. 

The invigorating taste of mint in these products is often complemented by spearmint or menthol. The excellent flavour combined with the sharp nicotine envelops your core and senses like a Siberian winter.


Types of Siberia snus products

Siberia products can be categorized based on the bag size and moisture content. Generally, Siberia offers:


Top Siberia snus products

Siberia is a brand that only offers extremely strong snus. You won't find any mild wish wash in their shop. Here are some Siberia products that you should try out

  1. Siberia -80 Degrees White Dry Portion
  2. Siberia Black Portion
  3. Siberia Slim White Dry
  4. Siberia -80°c White Portion
  5. Siberia -80 Brown Portion


We now sell Siberia snus to Americans

Yes! We deliver snus products to the US safely and as quickly as possible. Siberia snus happens to be a top-seller around the world, which includes the US. Along with General snus cans, Siberia dip is also highly demanded in the US.


Shipment guidelines for Siberia pods

As far as the shipment is concerned, we ship our snus cans around the world. Because of our fast shipping policy, shipments to the US take the usual amount of time, i.e. 3 to 4 working days. Like all the other products on


Stronger & safer than American dip

The short answer is YES! Siberia Dip is the strongest dip in the world. An original portion of this dip has enough nicotine to wake up a skeleton. We kind you not when we say that nothing could come close to the quality of Siberia dip.

For perspective, Skoal Long Cut Wintergreen is the strongest American dipping tobacco. Siberia dip based on the classic Swedish tobacco is way stronger. Compared to Skoal Long, you will get a good nicotine kick that lasts longer.


Using snus versus non-smoking

Our emphasis was on studies that compare the risk of disease and death amongst non-smoking users of snus with that of non-tobacco users. The reason for this emphasis was that any adjustment made for smoking habits without data about smoking volume or duration, will be inaccurate and incomplete. If smokers who also use snus smoke less than those who only smoke cigarettes, this may lead to an over-adjustment of the smoking component and a consequential underestimation of the effect of snus.

In some studies, the risk estimates for snus-exposed groups were not significantly different from the control groups, and the estimates had broad and asymmetrical confidence intervals. Although such results do not provide a basis for unambiguous conclusions, they are often incorrectly interpreted as an absence of risk.


Risk of disease

We found that the use of snus increases the risk of cancer of the oesophagus, stomach, pancreas and rectum. Using snus also increases the risk of high blood pressure, increases the mortality rate after cancer, myocardial infarction and cerebral stroke, and increases the risk of non-affective psychosis, type-2 diabetes, metabolic syndrome, weight gain and obesity. We also found evidence to suggest that the use of snus may reduce the risk of Parkinson's disease. Estimated risk per 100,000 users of snus, based on the control groups (non-users of tobacco products) in studies included in the evidence report on health risks of snus from the Norwegian Institute of Public Health The study populations are not directly comparable because of dissimilar follow-up periods and age distribution. RR = relative risk, HR = hazard ratio, OR = odds ratio, MD = mean difference


Insufficient information about exposure

Insufficient data about possible changes in the participants' tobacco habits during the follow-up period was a common weakness of population studies with a long follow-up period. Good information about exposure and health outcomes is essential for population studies to reveal the true effects of exposure. Several of the population studies that we examined, were not originally designed to study the effects of using snus. In the cohort with the largest number of participants, use of snus was recorded as one of several life style factors, and the analyses were most often based exclusively on the first registration. Many participants may have discontinued using snus in the course of the follow-up period, as suggested by studies that repeatedly recorded the participants' snus habits. Any change in this habit will lead to misclassification of exposure, which in turn may weaken the association between using snus and health outcomes, potentially making it impossible to prove such a link.


Impact of snus on women and fetuses

Among women who used snus throughout pregnancy, we found an increased risk of stillbirth, premature delivery, small-for-gestational age fetus, low birth weight, caesarean section, neonatal arrhythmia, oral cleft malformations and neonatal apnoea. A higher level of the nicotine metabolite cotinine detected in the urine of neonates confirmed nicotine exposure from maternal snus use. Long-term effects of using snus while pregnant have also been found: at 5–6 years of age, children of mothers using snus during pregnancy had higher blood pressure, more frequent arrhythmias and stiffer artery walls than children of mothers not using any tobacco products.

Using snus also increases the risk of high blood pressure, increases the mortality rate after cancer, myocardial infarction and cerebral stroke, and increases the risk of non-affective psychosis, type-2 diabetes, metabolic syndrome, weight gain and obesity


Interpretation of results

The literature often reports the risk of health outcomes as relative risk estimates, which says little about the impact on public health, i.e. the numbers affected. We therefore chose to calculate the absolute risk increase for 100,000 users of snus based on the absolute risk found in the control group (Table 1). Where the use of snus could worsen the disease prognosis, we calculated the absolute increase in risk per 1,000 patients who used snus.


Poorer prognosis

Our calculations show that using snus results in 44 more fatalities per 1,000 patients after a cancer diagnosis, 51 more fatalities after myocardial infarction, 35 more fatalities after cerebral stroke, and 73 more fatalities during a long follow-up period (17 years) after cerebral stroke. Patients who quit using snus after a myocardial infarction halve the risk of dying in the next two years (5).

The estimated risk of dying within 28 days of both myocardial infarction and cerebral stroke had broad confidence intervals that only just included 1. The results are thus borderline statistically significant, but indicate that the risk of dying in the first four weeks after myocardial infarction and cerebral stroke increased by 28 and 42 per cent respectively. These results are supported by a considerably reduced risk of dying after a myocardial infarction when quitting the snus habit and a statistically significant increased mortality rate associated with the use of snus in a study that involved a long follow-up period after cerebral stroke. Evidence of the vasoconstrictive effect of nicotine and the ability of snus to increase blood pressure and adversely affect the endothelial cells of blood vessels also supports our conclusion that snus increases the mortality rate after myocardial infarction and cerebral stroke.


Different conclusions for pancreatic cancer and cardiovascular diseases

In some cases, our assessment differs from that of the authors of the original study. One example concerns pancreatic cancer. In a study from 2007, Luo et al. investigated a cohort of Swedish construction workers who had been followed up for a period of up to 27 years (3). With close to 280,000 participating men, this is the largest available Swedish cohort with registered snus habits. Luo et al. found that the use of snus doubled the risk of pancreatic cancer. Nine years later, the same construction workers were included in a pooled analysis with men from eight other Swedish cohorts. Araghi et al., who conducted the pooled analysis, found a hazard ratio (HR) of 1.07 (95 % CI 0.77–1.50) for pancreatic cancer among men who used snus only, compared with men who did not use snus and did not smoke (6). The confidence interval suggested a potential risk reduction of up to 23 per cent as well as a potential risk increase of up to 50 per cent.

Users of snus who quit after myocardial infarction halve the risk of dying in the aftermath


We therefore have most confidence in the study conducted by Luo et al. (3), which shows a doubling of the risk, i.e. an effect that is sufficiently strong to qualify for an upgrade according to the GRADE method. We also know that the tobacco-specific nitrosamine NNK (nicotine-derived nitrosamine ketone) causes pancreatic cancer in animal studies and that exposure to other tobacco products such as cigarette smoking leads to a similar increase in the risk of pancreatic cancer. It has been proven that the risk of this form of cancer decreases to the background level after smoking cessation. It is reasonable to assume that the same is the case on snus cessation.


Main message to healthcare personnel

The use of Swedish moist oral snuff (snus) is associated with an increased risk of cancer, high blood pressure, increased mortality after cancer, cardiovascular diseases, increased risk of psychosis, obesity, metabolic syndrome – and (in cases of high consumption) increased risk of type-2 diabetes. Users of snus who quit after myocardial infarction halve the risk of dying in the aftermath. Using snus during pregnancy is harmful to the child. The high rate of snus use is therefore worrying.